Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2015

Open Access 01-12-2015 | Study protocol

Comparison of 6 % hydroxyethyl starch and 5 % albumin for volume replacement therapy in patients undergoing cystectomy (CHART): study protocol for a randomized controlled trial

Authors: Tobias Kammerer, Florian Klug, Michaela Schwarz, Sebastian Hilferink, Bernhard Zwissler, Vera von Dossow, Alexander Karl, Hans-Helge Müller, Markus Rehm

Published in: Trials | Issue 1/2015

Login to get access

Abstract

Background

The use of artificial colloids is currently controversial, especially in Central Europe Several studies demonstrated a worse outcome in intensive care unit patients with the use of hydroxyethyl starch. This recently even led to a drug warning about use of hydroxyethyl starch products in patients admitted to the intensive care unit. The data on hydroxyethyl starch in non–critically ill patients are insufficient to support perioperative use.

Methods/Design

We are conducting a single-center, open-label, randomized, comparative trial with two parallel patient groups to compare human albumin 5 % (test drug) with hydroxyethyl starch 6 % 130/0.4 (comparator). The primary endpoint is cystatin C ratio, calculated as the ratio of the cystatin value at day 90 after surgery relative to the preoperative value. Secondary objectives are inter alia the evaluation of the influence of human albumin and hydroxyethyl starch on further laboratory chemical and clinical parameters, glycocalyx shedding, intensive care unit and hospital stay and acute kidney injury as defined by RIFLE criteria (risk of renal dysfunction, injury to the kidney, failure of kidney function, loss of kidney function, and end-stage kidney disease) criteria.

Discussion

There is a general lack of evidence on the relative safety and effects of hydroxyethyl starch compared with human albumin for volume replacement in a perioperative setting. Previously conducted studies of surgical patients in which researchers have compared different hydroxyethyl starch products included too few patients to properly evaluate clinical important outcomes such as renal function. In the present study in a high-risk patient population undergoing a major surgical intervention, we will determine if perioperative fluid replacement with human albumin 5 % will have a long-term advantage over a third-generation hydroxyethyl starch 130/0.4 on the progression of renal dysfunction until 90 days after surgery.

Trial registration

EudraCT number 2010-018343-34. Registered on 11 January 2010.
Appendix
Available only for authorised users
Literature
1.
Jacob M, Chappell D, Rehm M. Clinical update: perioperative fluid management. Lancet. 2007;369:1984–6.CrossRefPubMed
2.
Chappell D, Jacob M, Hofmann-Kiefer K, Conzen P, Rehm M. A rational approach to perioperative fluid management. Anesthesiology. 2008;109:723–40.CrossRefPubMed
3.
Hüter L, Simon TP, Weinmann L, Schuerholz T, Reinhart K, Wolf G, et al. Hydroxyethyl starch impairs renal function and induces interstitial proliferation, macrophage infiltration and tubular damage in an isolated renal perfusion model. Crit Care. 2009;13:R23. doi:10.​1186/​cc7726.CrossRefPubMedPubMedCentral
4.
Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2008;358:125–39.CrossRefPubMed
5.
Schabinski F, Oishi J, Tuche F, Luy A, Sakr Y, Bredle D, et al. Effects of a predominantly hydroxyethyl starch (HES)-based and a predominantly non HES-based fluid therapy on renal function in surgical ICU patients. Intensive Care Med. 2009;35(9):1539–47. doi:10.​1007/​s00134-009-1509-1.CrossRefPubMed
6.
The FLUIDS Study Investigators for the Scandinavian Critical Care Trials Group. Preferences for colloid use in Scandinavian intensive care units. Acta Anaesthesiol Scand. 2008;52:750–8.CrossRef
7.
The SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350:2247–56.CrossRef
8.
SAFE Study Investigators. Effect of baseline serum albumin concentration on outcome of resuscitation with albumin or saline in patients in intensive care units: analysis of data from the saline versus albumin fluid evaluation (SAFE) study. BMJ. 2006;333:1044.CrossRef
9.
SAFE Study Investigators. Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med. 2007;357:874–84.CrossRef
10.
Jacob M, Chappell D. Saline or albumin for fluid resuscitation in traumatic brain injury. N Engl J Med. 2007;357(25):2634–5.CrossRefPubMed
11.
Wilkes MM, Navickis RJ. Patient survival after human albumin administration a meta-analysis of randomized, controlled trials. Ann Intern Med. 2001;135:149–64.
12.
Jacob M, Bruegger D, Rehm M, Welsch U, Conzen P, Becker BF. Contrasting effects of colloid and crystalloid resuscitation fluids on cardiac vascular permeability. Anesthesiology. 2006;104:1223–31.CrossRefPubMed
13.
Jacob M, Paul O, Mehringer L, Chappell D, Rehm M, Welsch U, et al. Albumin augmentation improves condition of guinea pig hearts after 4 hr of cold ischemia. Transplantation. 2009;87:956–65.CrossRefPubMed
14.
Blasco V, Leone M, Antonini F, Geissler A, Albanèse J, Martin C. Comparison of the novel hydroxyethyl starch 130/0.4 and hydroxyethyl starch 200/0.6 in brain-dead donor resuscitation on renal function after transplantation. Br J Anaesth. 2008;100:504–8.CrossRefPubMed
15.
Van der Linden PJ, De Hert SG, Deraedt D, Cromheecke S, De Decker K, De Paep R, et al. Hydroxyethyl starch 130/0.4 versus modified fluid gelatin for volume expansion in cardiac surgery patients: the effects on perioperative bleeding and transfusion needs. Anesth Analg. 2005;101:629–34.CrossRefPubMed
16.
Hartog CS, Kohl M, Reinhart K. A systematic review of third-generation hydroxyethyl starch (HES 130/0.4) in resuscitation: safety not adequately addressed. Anesth Analg. 2011;112:635–45.CrossRefPubMed
17.
18.
19.
Mussap M, Dalla Vestra M, Fioretto P, Saller A, Varagnolo M, Nosadini R, et al. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int. 2002;61:1453–61.CrossRefPubMed
20.
Grubb A, Nyman U, Björk J, Lindström V, Rippe B, Sterner G, et al. Simple cystatin C–based prediction equations for glomerular filtration rate compared with the modification of diet in renal disease prediction equation for adults and the Schwartz and the Counahan–Barratt prediction equations for children. Clin Chem. 2005;51:1420–31.CrossRefPubMed
21.
Müller HH, Schäfer H. Adaptive group sequential designs for clinical trials: combining the advantages of adaptive and of classical group sequential approaches. Biometrics. 2001;57(3):886–91.CrossRefPubMed
22.
Müller HH, Schäfer H. A general statistical principle for changing a design any time during the course of a trial. Stat Med. 2004;23(16):2497–508.CrossRefPubMed
23.
Evangelopoulos AA, Vallianou NG, Bountziouka VP, Giotopoulou AN, Bonou MS, Barbetseas J, et al. The impact of demographic characteristics and lifestyle in the distribution of cystatin C values in a healthy Greek adult population. Cardiol Res Pract. 2011;2011:163281.
24.
25.
Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute Dialysis Quality Initiative workgroup. Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8:R204–12. doi:10.​1186/​cc2872.CrossRefPubMedPubMedCentral
Metadata
Title
Comparison of 6 % hydroxyethyl starch and 5 % albumin for volume replacement therapy in patients undergoing cystectomy (CHART): study protocol for a randomized controlled trial
Authors
Tobias Kammerer
Florian Klug
Michaela Schwarz
Sebastian Hilferink
Bernhard Zwissler
Vera von Dossow
Alexander Karl
Hans-Helge Müller
Markus Rehm
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Trials / Issue 1/2015
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-015-0866-z

Other articles of this Issue 1/2015

Trials 1/2015 Go to the issue

Study protocol

Titanium versus absorbable tacks comparative study (TACS): a multicenter, non-inferiority prospective evaluation during laparoscopic repair of ventral and incisional hernia: study protocol for randomized controlled trial

Research

Risk of selection bias in randomised trials

Commentary

Reducing the confusion and controversies around pragmatic trials: using the Cardiovascular Health Awareness Program (CHAP) trial as an illustrative example

Study protocol

Personalized versus standardized dosing strategies for the treatment of childhood amblyopia: study protocol for a randomized controlled trial

Study protocol

Effect of laser acupuncture on obesity: study protocol for a randomized controlled trial

Methodology

Designing a stepped wedge trial: three main designs, carry-over effects and randomisation approaches